Buy Dr. Reddy’s Laboratories: target of Rs 5550: Sharekhan

"India’s specialty chemicals industry is a decadal growth opportunity and it is still not too late to participate in the value creation process. We prefer CRAMS/CSM players Navin Fluorine (Navin) and PI Industries (PI) as they provide long-term earnings visibility. We also like UPL due to robust growth outlook and reducing debt concerns and SRF due to rising contribution from the chemicals business," JM Financial research report.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Sharekhan's research report on Dr. Reddy’s Laboratories

DRL’s India business is expected to stage a double digit growth going ahead backed by a pick up across pain and respiratory therapy while the other therapies are expected to sustain the growth momentum. The performance of the US business is likely to be under stress in the near term due to sustained price erosion and slower product approvals. However over the long term, a strong product pipeline comprising limited competition products provides ample visibility on growth. DRL’s Q4Fy22 performance is expected to be weak as higher cost pressures and elevated raw material prices could result in a OPM’s declining on a yoy basis.

Outlook

We retain Buy recommendation on Dr Reddys Laboratories (DRL) with a revised PT of Rs 5,550.

More Info

At 17:30 Dr Reddys Laboratories was quoting at Rs 4,372.50, down Rs 7.35, or 0.17 percent.

It has touched an intraday high of Rs 4,405.30 and an intraday low of Rs 4,329.30.

It was trading with volumes of 9,710 shares, compared to its thirty day average of 21,453 shares, a decrease of -54.74 percent.

In the previous trading session, the share closed down 1.14 percent or Rs 50.30 at Rs 4,379.85.

The share touched its 52-week high Rs 5,613.65 and 52-week low Rs 3,655.00 on 07 July, 2021 and 04 March, 2022, respectively.

Currently, it is trading 22.39 percent below its 52-week high and 19.21 percent above its 52-week low.

Market capitalisation stands at Rs 72,769.70 crore.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More